Korean J Hematol.  2011 Sep;46(3):207-208. 10.5045/kjh.2011.46.3.207.

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma

• Park SK
• Yun J
• Kim SH
• Hong DS

• KMID: 2252007
• DOI: http://doi.org/10.5045/kjh.2011.46.3.207

Abstract

No abstract available.

MeSH Terms

B-Lymphocytes
Lymphoma, B-Cell

Reference

1. Jang G, Yoon DH, Kim S, et al. Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. Korean J Hematol. 2011; 46:103–110. PMID: 21747882.

2. Krol AD, le Cessie S, Snijder S, et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003; 14:131–139. PMID: 12488305.

3. Cavalli F, Stein H, Zucca E, editors. Extranodal lymphomas: pathology and managemen. 2008. 1st ed. London, UK: Informa Healthcare;p. 3–9.

4. López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005; 23:2797–2804. PMID: 15728226.

5. Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol. 2004; 124:151–159. PMID: 14687024.